{"slug":"essential-thrombocythaemia","tag":"essential-thrombocythaemia","variants":["essential-thrombocythaemia"],"description":"No description yet","count":3,"kinds":{"cancer":1,"trial":2},"related":[{"slug":"mpn","tag":"mpn","shared":3}],"records":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/","tldr":"Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."},{"id":"pt-1","kind":"trial","name":"PT-1 (Primary Thrombocythaemia 1)","route":"/trials/pt-1/","status":"positive","tldr":"PT-1 is the trial that made hydroxyurea the first-line drug in high-risk ET: anagrelide gave more arterial clots, more serious bleeding and more progression to myelofibrosis."},{"id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","status":"negative","tldr":"MAJIC-ET found that ruxolitinib was no better than the usual second-line drugs at controlling platelets in ET, although it eased itching and other symptoms."}]}